the evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with all
Published 1 year ago • 70 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
2:21
improving adult all treatment: pediatric regimens & adding inotuzumab
-
1:13
phase ii study of inotuzumab ozogamicin in mrd b-all
-
4:08
inotuzumab ozogamicin for treating pediatric r/r all
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
3:03
novel all treatment strategies: inotuzumab ozogamicin
-
15:07
introduction to neonatal jaundice
-
8:36
treating cd33-positive aml with gemtuzumab ozogamicin
-
2:50
extracorporeal blood oxygenation and ozonation (ebo2) therapy
-
3:29
is inotuzumab ozogamicin with low-dose chemotherapy effective in treating all in elderly patients?
-
4:44
emerging novel approaches for all: inotuzumab ozogamicin
-
3:28
inotuzumab as a potential treatment for elderly patients with all
-
3:04
immunotherapy for frontline treatment of all: inotuzumab ozogamicin and blinatumomab
-
1:37
phase ii trial of inotuzumab ozogamicin to treat mrd b-all
-
0:48
the mechanism of action of inotuzumab ozogamicin
-
1:25
how the role of transplant in all is evolving with the introduction of novel immunotherapies
-
1:09
the future of inotuzumab therapy for all
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:31
improving the soc for all with inotuzumab
-
2:19
addition of inotuzumab to allosct conditioning regimen in relapsed cd22 ( ) lymphoid malignancies
-
1:03
updated results of hyper-cvad and blinatumomab /- inotuzumab ozogamicin in newly-diagnosed b-all
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)